[ad_1]

OBJECTIVE:

To assess the impact of oral cannabidiol ( CBD) administration in addition to traditional antiepileptic therapy on seizure frequency in dogs with idiopathic epilepsy.

Design and style:

Randomized blinded controlled clinical trial.

ANIMALS:

26 client-owned dogs with intractable idiopathic epilepsy.

PROCEDURES:

Dogs have been randomly assigned to a CBD (n = 12) or placebo (14) group. The CBD group received CBD-infused oil (two.five mg/kg [1.1 mg/lb], PO) twice every day for 12 weeks in addition to current antiepileptic remedies, and the placebo group received noninfused oil beneath the exact same circumstances. Seizure activity, adverse effects, and plasma CBD concentrations have been compared involving groups.

Outcomes:

two dogs in the CBD group created ataxia and have been withdrawn from the study. Just after other exclusions, 9 dogs in the CBD group and 7 in the placebo group have been integrated in the evaluation. Dogs in the CBD group had a important (median transform, 33%) reduction in seizure frequency, compared with the placebo group. Nonetheless, the proportion of dogs thought of responders to therapy (≥ 50% reduce in seizure activity) was comparable involving groups. Plasma CBD concentrations have been correlated with reduction in seizure frequency. Dogs in the CBD group had a important improve in serum alkaline phosphatase activity. No adverse behavioral effects have been reported by owners.

CONCLUSIONS AND CLINICAL RELEVANCE:

While a important reduction in seizure frequency was accomplished for dogs in the CBD group, the proportion of responders was comparable involving groups. Offered the correlation involving plasma CBD concentration and seizure frequency, added study is warranted to establish no matter if a larger dosage of CBD would be successful in minimizing seizure activity by ≥ 50%.

[ad_2]